Over the last decade, the treatment of patients with advanced non–small cell lung cancer
(NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment …

Introduction Greater understanding of molecular pathways important in cell growth and
proliferation of thoracic malignancies, particularly non-small cell lung cancer (NSCLC), has …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Advances in biomarker‐driven therapies for patients with nonsmall cell lung cancer
(NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for …

Background An ASCO taskforce comprised of representatives of oncology clinicians, the
American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 …

For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Lung cancer is diagnosed in more than 1.8 million people yearly and remains the leading
cause of cancer deaths in both developing and developed countries, with survival at 5 years …